Comparison of the antiemetic efficacy of tropisetron and chlorpromazine after cytotoxic therapy Sitotoksik tedavi sonrasi tropisetron ile klorpromazinin antiemetik etkilerinin karsilastirilmasi


Ozalp S., YALÇIN Ö. T., Yildirim A., Bayirli R.

Jinekoloji ve Obstetri Bulteni, cilt.7, sa.1, ss.10-15, 1998 (Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 7 Sayı: 1
  • Basım Tarihi: 1998
  • Dergi Adı: Jinekoloji ve Obstetri Bulteni
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.10-15
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective: To compare the efficacy of tropisetron and chlorpromazine for prevention of nausea and vomiting which occur after cytotoxic therapy. Study Design: Thirty cases, who were administered combined cisplatine and cyclophosphamide chemotherapy for advanced malignant epithelial ovarian neoplasm, were included in the study. Anti-emetic efficacy and adverse effects of tropisetron given during a total of 80 chemotherapy administrations and chlorpromazine given during a total of 70 chemotherapy administrations in these cases, were evaluated prospectively. Results: Considering the prevention of vomiting, tropisetron was observed to achieve complete control in 70.0 %, major control in 21.3 %, minor control in 3.7 %, and no control in 5.0 % of the chemotherapy administrations, while these rates were found as 14.3 %, 17.1%, 35.7 % and 32.9 % respectively for chlorpromazine. The succes rate of tropisetron for prevention of vomiting (complete and major control) was observed to be significantly higher than that of chlorpromazine (p<0.01). Moreover, tropisetron (5.0 %) was observed to prevent severe nausea more effectively than chlorpromazine (15.3 %) (p<0.05). When the adverse effects developed after these two medications were compared, sedation, mouth dryness, headache, tremor and dizziness were observed more frequently after chlorpromazine treatment (p<0.01). Conclusion: Compared to chlorpromazine, tropisetron was suggested to be more efficient and safe medication for prevention of nausea and vomiting, developing after cytotoxic therapy.